Avidin is a diversified biotech firm with a dual focus on therapeutic discovery and molecular diagnostics. Its most advanced program is Q134R, a clinical candidate for Alzheimer's disease developed in partnership with Aperus Pharma. The company also maintains active research in oncology and inflammation, and provides preclinical services and diagnostic products, supported by international scientific and industrial collaborations.
Integrated platform combining single-cell genomics for digital mRNA/miRNA expression analysis, multiple screening platforms for small molecules/lipids/nanoparticles, and a proprietary chemical library for drug discovery.
Funding History
2
Total raised:$3M
Seed$2.5MHiventures
Grant$500KHungarian National Research, Development and Innovation Office
Opportunities
The partnership on Q134R for Alzheimer's provides a path to the high-value neurodegenerative market without bearing full clinical costs.
The growing demand for molecular diagnostics, especially post-pandemic and for early cancer detection, offers a scalable revenue stream for the diagnostics division.
Risk Factors
Heavy reliance on the success of a single, partnered clinical candidate in Alzheimer's disease, a area with a high failure rate.
As a private company, funding the advancement of multiple preclinical programs while competing in crowded therapeutic and diagnostic markets presents significant financial and operational challenges.
Competitive Landscape
In therapeutics, Avidin faces intense competition from large pharma and well-funded biotechs in oncology and Alzheimer's. In diagnostics, it competes with global IVD giants and nimble startups. Its differentiation lies in its integrated genomics/screening platform and cost-effective service base in Eastern Europe.
